Seeking Alpha
View as an RSS Feed

Vuru  

View Vuru's Articles BY TICKER:
  • Bleak Outlook For Sanofi In The Near-Term
    Wed, Feb. 25 SNY 11 Comments

    Summary

    • The company's earnings remain highly sensitive to the changing US diabetes market.
    • Analyst expectations for 2014-2016 show relatively flat growth.
    • Valuation calculations show the company trading close to fair value.
  • Near-Term Risks Could Affect AstraZeneca Investors
    Mon, Feb. 23 AZN 1 Comment

    Summary

    • Management guidance shows small revenue growth and negative EPS growth for 2015.
    • Key catalysts for the company include patent expirations, drug testing and foreign exchange headwinds.
    • DCF valuations peg the company trading 10% above intrinsic value.
  • Macro Headwinds Could Take Their Toll On Philip Morris In 2015
    Thu, Feb. 12 PM 5 Comments

    Summary

    • Headwinds could come in the form of relative economic underperformance and FX declines in key developed markets.
    • Particularly on the company's radar are business units in Russia, South Korea and Japan.
    • Valuation metrics show the company is trading well above intrinsic value.
  • Vodafone Poised To Recapture European Market
    Thu, Jan. 29 VOD Comment!

    Summary

    • The economic downturn in Europe has weakened the company's earnings in recent years.
    • The company's $10B investment in infrastructure in Europe will help it become the market leader in the LTE market.
    • 5% expected dividend yield in 2016 will entice investors.
  • Cognizant Poised To Outpace The Market In 2015
    Wed, Jan. 28 CTSH 3 Comments

    Summary

    • Management recently revised guidance for FY15 upward on the expectation of strong revenue growth.
    • Recent company acquisitions have totaled $3.5B in contractual value.
    • Key acquisitions include Health Net and TriZetto.
  • Unilever Among The Most Exposed To Slowing Global Demand
    Fri, Jan. 23 UL 13 Comments

    Summary

    • The company missed on sales in the 3Q of 2014, mainly caused by a miss on sales volumes.
    • The company plans on creating a standalone spreads company to help the situation.
    • Unilever likely gives limited potential to investors in there near-term as they remain highly exposed to market conditions.
  • Winners Of Low Oil
    Mon, Jan. 19 AAL, COST, DAL 1 Comment

    Summary

    • Many industries are facing a new reality in the wake of suppressed crude prices.
    • Low oil reduces company input prices and puts more money in the hands of their consumers.
    • Industries to watch include airlines and food retailers.
  • Honda Telling A Different Story In Developing Vs. Developed Markets
    Wed, Jan. 14 HMC 14 Comments

    Summary

    • Honda struggling to create sales growth in developed markets.
    • Near-term costs from voluntary recalls and investment should affect earnings in second half 2015.
    • Proper management of incentive plans as well as the volume-increasing and the cost reducing effect of the launch of a new plant in Mexico helps in the long-term.
  • 4 Reasons To Buy Oil And Gas Now
    Sat, Jan. 10 XLE, ERX, VDE 41 Comments

    Summary

    • Investors are expressing their willingness to wait and see how things play out before investing back in energy.
    • This is a dangerous game as markets can correct themselves quickly.
    • Investors should be focusing on companies with strong balance sheets and favourable fundamentals in comparison to their industry. The time to buy is now.
  • 3M Likely To Continue Strong Run In 2015
    Wed, Jan. 7 MMM 6 Comments

    Summary

    • 3M has had a strong run in the past couple of years and investors are wondering if this will continue.
    • Management has released positive guidance for 2015 to signal its belief in a strong year to come for the company.
    • Catalysts include growth in emerging markets, lowered cost base and a track record of innovation.
  • Abbott Labs Well Positioned For Success In 2015
    Dec. 29, 2014 ABT Comment!

    Summary

    • Abbott Labs is a leading health care company that has been steadily growing since their spinoff of AbbVie at the end of 2012.
    • The company posted strong 3Q results that show the company is likely poised for a strong 2015.
    • The company provides upside over the medium to long-term as management now seems clearly focused on reaccelerating growth through improving execution and investing in new technologies and geographies via M&A.
  • Vale S.A.'s Prospects Heavily Tied To China
    Dec. 25, 2014 VALE 8 Comments

    Summary

    • The company had missed expectations in terms of both gross and net margins in the 3Q and has been struggling as a company since early 2011.
    • Analysts are questioning VALE’s ability to maintain dividends, retain an investment grade credit rating and continue with its current capital investment program.
    • Uncertainty in iron-ore prices resulting from a slowdown in China and slow economic recovery in Europe will restrict VALE’s ability to generate FCF over the near term.
  • J.C. Penney Has Plan In Place, Investors Should Still Stay Clear
    Dec. 15, 2014 JCP 19 Comments

    Summary

    • J.C. Penny's share price has seen a steep drop since reaching a five-year high in 2012.
    • Recent trouble has forced management to consider growth initiatives with a focus on increasing online earnings.
    • In a highly competitive, fragmented and economically sensitive industry, the risk to investors is high.
  • Cloud Solutions, Big Data And Storage Shifts All Poised To Help EMC
    Dec. 8, 2014 EMC 1 Comment

    Summary

    • EMC sells the IT industry’s broadest range of information infrastructure and virtual infrastructure technologies, services and solutions.
    • The company is the No. 1 storage vendor globally with over 30% market share and is poised to continue being a leader.
    • The company is well positioned to benefit from an eventual increase in storage investments as CIOs refine their strategies around cloud, big data and new architecture investments.
  • Model Streamlining Will Reward DuPont Investors
    Dec. 5, 2014 DD 5 Comments

    Summary

    • E.I. Dupont De Nemours & Co. (DD) is a 36B manufacturer of agricultural products, photovoltaics and consumer electronics such as TiO2, refrigerants, protection products and construction.
    • Our grade shows a reflection of the company’s financial strength, economic moat, management ability and dividend/buyback trends - and indicated theres more to the story.
    • DuPont provides potential for investors in the long-term as agricultural business should have improved performance, benefits from streamline are realized and the global recovery boosts earnings.
  • Aetna Has Potential For Investors At A Fair Price
    Nov. 24, 2014 AET 6 Comments

    Summary

    • Aetna Inc. is one of the leading diversified healthcare benefits companies, serving an estimated 44 million people across the globe.
    • AET looks fairly valued at current levels, with potential over the long-term.
    • This potential is on the basis of pressure from escalating commercial cost trend and a balance sheet that will allow for acquisitions.
  • FedEx Expected To Continue Rapid Growth As U.S. Economy Recovers
    Nov. 22, 2014 FDX Comment!

    Summary

    • FedEx Corp. is a global leader in parcel delivery services and provides customers and businesses worldwide with a broad portfolio of transportation, e-commerce and business services.
    • As the US economy continues to improve, FedEx expects the US economy to continue to lead the way in terms of growth for top line revenues.
    • FedEx provides potential upside from current levels over the medium- to long-term, as expectations about a stronger y/y peak season and international volumes continue to improve.
  • Medical Breakthroughs On The Horizon For Merck
    Nov. 20, 2014 MRK 2 Comments

    Summary

    • Merck (MRK) is a global health care company that includes prescription medicines; vaccines, biologic therapies, animal health and consumer care products.
    • 3Q results overshadowed Keytruda receiving a broad breakthrough therapy designation for advanced NSCLC that’s progressed after platinum-based chemotherapy.
    • The Oct 2013 restructuring has laid a foundation for better than anticipated EPS growth as faster than expected cost cuts will place an upward bias to MRK’s EPS outlook.
  • UPS Sensitive To Industry Competition And Macro Factors
    Nov. 11, 2014 UPS 3 Comments

    Summary

    • UPS offers customs-cleared, door-to-door delivery and is among the top providers in most international markets.
    • UPS plans to focus on growth in both the B2B and B2C channels.
    • Limited potential over the long-term because industry fundamentals have been deteriorating .
  • Dow's NPV Projects And Proceeds Will Reward Shareholders
    Nov. 7, 2014 DOW 6 Comments

    Summary

    • Dow Chemical is the largest US chemical company in terms of revenue.
    • DOW plans on creating positive NPV projects and divest in unneeded assets to create shareholder value.
    • The company has plenty of upside in the long-term on the basis of earnings, dividend yield and proceeds from sale of assets.
  • Superior Business Model Gives Costco Competitive Advantage
    Nov. 5, 2014 COST 9 Comments

    Summary

    • Costco has seen over 100% share price growth in the past five years.
    • Costco focuses on managing inventory and prices, employee empowerment and consumer membership.
    • Costo warrants a premium valuation (P/E of 28.79) and will continue to reward investors.
  • P&G Will Reward Shareholders Through Portfolio Consolidation And Cost Saving Measures
    Nov. 4, 2014 PG 2 Comments

    Summary

    • Growth in PG's top line revenue and margins has stagnated in recent years.
    • The consolidation of the company's portfolio was made necessary by the lack of overall earnings growth.
    • PG should become a much more nimble and responsive player in the market that could reward shareholders in the long-term.
  • Mosanto's Solid Fundamentals And High Growth Should Entice Investors
    Oct. 31, 2014 MON Comment!

    Summary

    • Monsanto has seen strong growth over the past years including share price growth of ~148% in the last five.
    • Strong management, financials, economic moat and dividends should lead investors to expect continued growth.
    • Share price looks fairly valued, although future growth leaves opportunity for investors in the long-term.
  • Target Will Not Abandon Canada, Neither Should Investors
    Oct. 29, 2014 TGT 6 Comments

    Summary

    • Target's share price has lost ~16% since entering the Canadian market.
    • New management has gone to great lengths to ensure they will make their Canadian operations profitable.
    • Canada only represents a small portion of the company's operations, and TGT's focus on dividends and digital growth will ensure Canada will not ruin the whole company for investors.
  • General Electric Remains A Safe Income Play In Market Turmoil
    Oct. 22, 2014 GE 3 Comments

    Summary

    • 3Q results for GE were mostly inline with estimates, bright spot was an increase in net earnings.
    • Large focus of the company's margins and earnings is the risky capital segment.
    • With little potential for capital gains because of slow growth and a shift of focus, investors should only consider GE for a guaranteed income stream above inflation.
  • Q3 Results Reaffirm Delta Air Lines' Potential For Investors
    Oct. 20, 2014 DAL 4 Comments

    Summary

    • Q3 Results for Delta were above analyst estimates in EPS, Revenue and EBITDA.
    • Share price catalysts include lower crude prices, strong economic moat, and insulation from geopolitical factors.
    • Delta remains a compelling investment in the airline sector given its corporate share gains, operational reliability and benefits from industry trends.
  • Looming Pullback And Competitive Industry Can't Scare Investors From Cardinal
    Oct. 18, 2014 CAH 2 Comments

    Summary

    • Cardinal Health's strong performance in the past five years has many investors predicting a looming correction.
    • Valuation metrics show CAH is trading well above its intrinsic value.
    • 30-year trend of dividend increases and potential from acquisitions and repositioning will continue to entice investors.
  • Verizon Leads The Telecom Sector For Investors
    Oct. 16, 2014 VZ 12 Comments

    Summary

    • We have seen strong ratings for Verizon and believes it is the clear leader in the Telecom sector for investors.
    • Investment rationale includes dividend yield, attractive entry and valuation, strong management and expected earnings growth.
    • 3Q announcement of earnings should be positive for Verizon.
  • Mixed Signals From McKesson Corporation Confuse Investors
    Oct. 14, 2014 MCK Comment!

    Summary

    • McKesson is a key holding in the healthcare and pharmaceutical sector that many investors have rode to a large gain in recent years.
    • The company has given mixed signals as to where the share price will head in the coming months.
    • The time is now for investors to lock in the gains they have received in the past five years, as the markets are becoming increasingly volatile.
  • After Large Oil And Gas Industry Pullback, The Time Is Now For Chevron
    Oct. 10, 2014 CVX 18 Comments

    Summary

    • Large pullback of both small and large market cap oil and gas companies presents opportunity for investors.
    • Chevron looks poised to grow and rebound from 15% loss in the past couple of months.
    • Investment is based on strong financials, economic moat, and dividend trends.
  • Royal Dutch Shell Looks Promising On Expectations Of Continued Growth
    Oct. 7, 2014 RDS.B 2 Comments

    Summary

    • Despite being one of the largest companies in the industry, Shell is still attractive.
    • Strong 2Q2014 results likely to replicated in 3Q2014.
    • Positive trends in free cash flow and dividends will continue to reward investors.
  • Exxon Mobil Warrants Premium Valuation Despite Volatile Financials
    Oct. 1, 2014 XOM 9 Comments

    Summary

    • Exxon Mobil warrants the premium valuation on the basis of strong brand equity, despite declining 2013 revenues.
    • Diversified product lines will insulate the company from macro events.
    • Fair valuation with limited potential for upside in the next 6 to 12 months.